Drug Trial Radar · NCT06217120
Reversing Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
64
Planned (sponsor's estimate)
Start
Nov 6, 2026
Primary completion
Apr 2027
Study completion May 2028
Sponsor
- Lead sponsor
- Montreal Heart InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Heart and Stroke Foundation of Canada; Centre hospitalier de l'Université de Montréal (CHUM)
- First posted
- Jan 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the impact of colchicine on the change in myocardial flow reserve (MFR), a marker for coronary microvascular dysfunction (CMD), compared to a matched placebo in patients with heart failure and ejection fraction above 40% (including patients with improved EF).
Conditions
- Heart Failure With Preserved Ejection Fraction
- Microvascular Coronary Artery Disease
Interventions
ColchicineDrug
Colchicine 0.6 mg once daily
PlaceboDrug
Placebo once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in myocardial flow reserve (MFR) between baseline and six monthsTime frame: Baseline and 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre de recherche du Centre hospitalier de l'Université de Montréal
Montreal, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.